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Abstract
There is a need to individualize assays for tumor molecular phenotyping, given variations in the 
differentiation status of tumor and normal tissues in different patients. To address this, we 
performed single-cell genomics of breast tumors and adjacent normal cells propagated for a short 
duration under growth conditions that enable epithelial reprogramming. Cells analyzed were either 
unselected for a specific subpopulation or phenotypically defined as undifferentiated and highly 
clonogenic ALDH+/CD49f+/EpCAM+ luminal progenitors, which express both basal cell and 
luminal cell-enriched genes. We analyzed 420 tumor cells and 284 adjacent normal cells for 
expression of 93 genes that included a PAM50 intrinsic subtype classifier and stemness-related 
genes. ALDH+/CD49f+/EpCAM+ tumor and normal cells clustered differently compared to 
unselected tumor and normal cells. PAM50 gene-set analyses of ALDH+/CD49f+/EpCAM+ 
populations efficiently identified major and minor clones of tumor cells, with the major clone 
resembling clinical parameters of the tumor. Similarly, a stemness-associated gene set identified 
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clones with divergent stemness pathway activation within the same tumor. This refined expression 
profiling technique distinguished genes truly deregulated in cancer from genes that identify 
cellular precursors of tumors. Collectively, the assays presented here enable more precise 
identification of cancer-deregulated genes, allow for early identification of therapeutically 
targetable tumor cell subpopulations, and ultimately provide a refinement of precision therapeutics 
for cancer treatment.
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Introduction
Gene expression-based molecular subclassification of tumors has gained clinical acceptance 
over the years and several tools have been commercialized for clinical use. Oncotype DX®, 
ProSigna® (PAM50) and MammaPrint (70-gene signature) are few such assays used in 
breast cancer management (1–4). A recent study suggested that MammaPrint assay aids in 
treatment decisions in early stage breast cancer, particularly to identify patients who may not 
need chemotherapy (5). Superiority of few of these assays in tumor classification compared 
to traditional immunohistochemistry based tumor classification is under debate. For 
example, while an earlier report claimed that PAM50 gathers more clinical information than 
immunohistochemistry of hormone receptors or ki67 (6), a recent study disputed such a 
claim (7).
While tumor classification based on gene expression patterns has been valuable clinically, 
further progress in these assays are needed to address two clinically important issues. First, 
it has been difficult to discern whether gene expression patterns in tumors that led to subtype 
classification are acquired due to genome aberrations or reflect cell type origin of tumors. 
Recent discovery of enormous inter-individual variation in gene expression in healthy tissues 
due to single nucleotide polymorphism in the regulatory regions of genomes makes it even 
harder to identify mutation-driven gene expression changes when normal cells from the 
same individual are not available for comparison (8,9). Second, tumor heterogeneity is a 
major clinical concern and the gene expression based assays may identify only major clones 
of the tumor. Therefore, an ideal assay should be able to identify cancer-specific aberration 
in gene expression and identify both major and minor clones of tumor cells.
As an initial step to address the above issues, we combined the latest progress in propagating 
normal and tumor cells from the same patient using an epithelial reprogramming assay (10) 
and single cell genomics of PAM50/stem cell associated genes (11). Unlike previously 
reported mammary epithelial growth conditions, which favors outgrowth of basal epithelial 
cells, reprogramming assay allows growth of stem, luminal progenitor and mature cells (12–
14). Assays that allow growth of breast epithelial cells of different differentiation state are 
essential because most breast cancers including basal-like breast cancers are suggested to 
originate from luminal progenitors and then differentiate/dedifferentiate into specific 
subtypes (15–18). We have recently demonstrated that tumor and adjacent normal cells are 
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in different differentiation state, which complicates our ability to distinguish mutation-driven 
gene expression changes in tumor from changes due to differences in differentiation state 
(14). In normal breast, >2000 genes are differentially expressed between stem/progenitor 
and differentiated cells (19) and these differences alone can account for tumor to normal 
tissue gene expression variations noted in large scale studies. To partially overcome this 
limitation, comparison between normal and tumors were done two ways. Assays included 
either bulk populations of epithelial cells or flow cytometrically enriched ALDH+/CD49f+/
EpCAM+ adjacent normal and tumor cells. In normal breast, these cells are considered to be 
undifferentiated highly clonogenic luminal progenitors that express both basal cell and 
luminal cell enriched genes (20). These assays, performed with cells from four tumors and 
adjacent normal tissues, enabled us to identify major and minor tumor clones and distinguish 
genes aberrantly expressed in tumors from genes whose expression pattern in tumor 
mirrored expression pattern in a subset of normal cells, which are likely the cellular 
precursors of tumors.
Materials and Methods
Primary tissues, culturing by reprogramming assay, and flow cytometry
Breast tissues used were de-identified and the Indiana University Institutional Review Board 
considered the protocol non-human subjects. Freshly obtained or cryopreserved tissues were 
minced, digested and subjected to culturing under modified reprogramming assay condition, 
as we have described recently (14). All cases used in the study were from mastectomy such 
that adjacent normal tissues were from regions as distant as possible from the tumor. Breast 
epithelial cells were collected by trypsinization and subjected to flow cytometry using 
antibodies described previously (14).
Single cell qRT-PCR
We used the C1 Single-Cell Auto Prep System (Fluidigm) for single-cell capture and pre-
amplification according to the manufacturer’s instructions (protocol 100-4904 K1). Both 
adjacent normal and tumor cells were grown for similar duration and in the same media and 
collected by flow cytometry before loading into the Integrated Fluidic Circuit (IFC). Briefly, 
a pool of all primers was prepared (100 μM). A lysis final mix, a reverse-transcriptase (RT) 
final mix and a pre-amplification (PreAmp) final mix were prepared and stored on ice. Next, 
the IFC for normal medium-size single cells (10 to 17 μm in diameter; Fluidigm, part 
number 100-5479), or the IFC for tumor large-size single cells (17–25μm in diameter; 
Fluidigm, part number 100-5758) was primed by adding C1 collection reagent, preloading 
reagent, blocking reagent and wash buffer into the IFC, and the IFC was placed into the C1 
Single-Cell Auto Prep System and the script ‘STA:Prime’ was run. Priming lasted 20 min, 
during which time cells were prepared for loading. Cells were pelleted and media was 
removed to create a concentration of 300,000 cells/mL. The single-cell suspension was 
mixed with a 3:2 ratio of Suspension Reagent (Fluidigm). After priming was completed, 
blocking and priming solutions were removed and 6 μl of cell mix was loaded onto the IFC. 
The IFC was placed back into the C1, and the script ‘STA:Cell Load’ was run. After cell 
loading was complete, the IFC was removed and single-cell capture sites were viewed using 
a microscope. Empty capture sites were noted, and the IFC was loaded with harvest reagent, 
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lysis final mix, RT final mix, and PreAmp final mix. The IFC was placed back into the C1, 
and the script ‘STA:PreAmp’ was run. After pre-amplification, the IFC was removed from 
the C1 and 3 μl of cDNA from each single cell was removed from individual collection wells 
and diluted in 25 μl of DNA suspension buffer (Fluidigm). The BioMark HD System 
(Fluidigm, protocol 68000088 K1) performs 96 individual qPCR reactions on the pre-
amplified cDNA from every single cell by utilizing 96 × 96 Dynamic Array Gene 
Expression IFCs (Fluidigm, part number BMK-M-96.96). For the qPCR reactions, SsoFast 
EvaGreen Supermix with Low ROX (Bio-Rad, part number 172-5211) and DNA Binding 
Dye (Fluidigm, part number 100-7609) were combined with individual cDNA samples. The 
cDNA mix was loaded into one side of the IFC, and primer pairs were loaded into the other 
side. The Juno System (Fluidigm) was used to prime the IFC and to distribute cDNA mix 
and primer pairs into reaction chambers inside the IFC. The IFC was then transferred into 
the BioMark HD System where qPCR reactions were controlled. Data from wells that 
contained more than one cell or non-viable cells were excluded from the analyses.
Data analyses
Real Time PCR Analysis software is a data analysis tool available from Fluidigm as part of 
the Singular Analysis Toolset and can be found at https://www.fluidigm.com/software. This 
toolset was built on the open source software R (Version 3.0.2). These software packages 
were used together to annotate and analyze data files generated from the BioMark HD. 
Hierarchical clustering (HC) was used to identify co-expressed genes. Heatmaps and violin 
plots were generated to compare sample groups. Analysis of variance (ANOVA) identified 
differentially expressed genes (Table S1). Principal component analysis (PCA) plots were 
generated to analyze outliers. Differentially expressed genes were subjected to Ingenuity 
pathway analyses (Ingenuity.com) to identify signaling networks uniquely active in tumor 
cells.
Immunohistochemistry
Immunohistochemistry procedure for MMP2 (antibody from Fisher Scientific #35-130-0Z) 
and quantitation have been described previously (21).
Results
Single cell genomics in cancer are mostly being used to decipher tumor heterogeneity, to 
develop evolutionary tree, and to map cellular hierarchy (11,22,23). This technique has also 
been used to detect clonal selection in patient-derived breast cancer xenografts (24). While 
DNA-based single cell genomics, which only compares copy number variations and 
mutations, have seen enormous progress with respect to detection and data analysis, there 
are several limitations in the use of this technology for RNA-based studies including inter-
individual variation in gene expression (9,25) and differences in differentiation state of 
tumor and normal (14). While perfection in elucidating cancer-specific gene expression 
changes may be impossible to achieve, refinement is possible by co-adapting several latest 
technologies. Figure 1A provides a schematic view of our approach towards achieving these 
goals.
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We propagated tumor and the adjacent normal tissues from four patients for a short duration 
using epithelial reprogramming assay (10). In our previous study, we have shown that in 
vitro propagation does not introduce any mutations and potentially allows expansion of 
minor clones (14). Tumors in Patient 1 and Patient 2 were ER+/Progesterone Receptor + (PR
+), whereas Patient 3 had an ER+/PR−/HER2+ tumor. Patient 4 had ER+/PR+ tumor with 
extensive metastasis. Patient 2 tumor also expressed HER2 at moderately higher levels (2+). 
We first performed phenotypic characterization of tumor and adjacent normal cells using 
CD49f and EpCAM antibodies. CD49f+/EpCAM−, CD49f+/EpCAM+ and CD49f−/
EpCAM+ cells are enriched for cells with stem/basal, luminal progenitor, and mature/
differentiated/non-clonogenic properties, respectively (26,27). As expected, tumors of 
Patients 1 and 2 had higher levels of differentiated cells compared to their corresponding 
adjacent normal cells, whereas both tumor and the adjacent normal cells of patient 3 were 
enriched for luminal progenitor cells (Figure 1B). Because of these differences in stem/
progenitor and differentiated cell hierarchy between tumor and normal cells, we adapted two 
strategies for characterizing primary cells. The first series included comparison of gene 
expression between randomly selected epithelial cells of tumor with normal, irrespective of 
their differentiation state. Epithelial cells were sorted using EpCAM and Jam-A/CD321 
antibodies to avoid contamination from any non-epithelial cells (Figure 2A). The second 
comparison included a phenotypically defined population in which gated ALDEFLUOR+ 
stem/progenitor cells (28) were fractionated based on the expression of CD49f and EpCAM 
into CD49f+/EpCAM+ luminal progenitor cells (Figure 2B). These cells in normal breast 
are considered to be undifferentiated luminal progenitors with overlapping luminal and basal 
cell gene expression pattern (20). Therefore, this selection procedure should enhance our 
ability to detect relevant cancer-specific gene expression differences in undifferentiated 
tumor cells. Between 27 and 93 cells per sample from isolated tumor or normal cells were 
subjected to qRT-PCR at the single cell level with stemness-associated and PAM50 gene 
primers.
Results of unselected tumor and normal epithelial cell comparison
Unsupervised hierarchical clustering of qRT-PCR results of stemness gene set showed clear 
separation of tumor from normal cells in both patient samples (Figure 3A and B). Tumor 
cells in both cases formed 2–3 minor clusters. However, tumor-enriched signaling networks 
differed between patient samples. A cluster of tumor cells in patient 1 showed enrichment of 
genes in the Wnt/βCatenin pathway (Figure 3C). Major signals responsible for cancer cell 
dedifferentiation and germ cell fate including SOX9 and SOX17 were upregulated in tumor 
cells compared to normal cells (29,30). A cluster of tumor cells in patient 2 likely have an 
activated Wnt/βCatenin pathway but it is most likely due to down regulation of APC and 
AXIN1, which are negative regulators of Wnt/β-Catenin pathway (Figure 3D) (31).
PAM50 gene set analyses enabled characterization of tumor and normal cells at multiple 
levels. First, Jam-A±EpCAM+ cells used in the analyses are epithelial because these cells 
expressed variable levels of keratin 5, keratin 17, epidermal growth factor receptor (EGFR) 
and ERBB2 (Figure 4A). Keratin 5 and 17, although expressed predominantly in basal cells, 
are expressed in luminal cells, particularly cells with luminal A breast cancer gene 
expression pattern (32). Second, most often cultured breast epithelial cells are enriched for 
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basal gene expression. Although our previous phenotypic analyses have shown that 
reprogramming assay conditions allow growth of both luminal and basal cells, this has not 
been proven at transcriptome level (14). In case of patient 1, normal cells were randomly 
distributed with one relatively large cluster with interspersed tumor cells and a minor cluster. 
The major cluster of normal cells expressed both basal and luminal cell-enriched genes, 
whereas the minor cluster expressed mostly luminal cell-enriched genes (Figure 4A). Tumor 
cells formed two well-separated clusters, one expressing predominantly luminal cell-
enriched genes and the other expressing both luminal and basal cell-enriched genes. Similar 
results in patient 2 with majority of tumor cells forming a single cluster that predominantly 
expressed luminal genes (Figure 4B). Majority of normal cells expressed both luminal and 
basal genes. Third, PAM50 gene set analyses confirmed heterogeneity in gene expression 
pattern in both tumor and normal cells of the same patient.
Tumor classification based on differential gene expression in phenotypically defined 
tumor and normal cells
To overcome difference in differentiation state between two cell types as a confounding 
factor in identification of cancer-specific gene expression changes, we performed the 
analyses in a phenotypically defined ALDH+/CD49f+/EpCAM+ subpopulation. CD49f+/
EpCAM− and/or CD44+/CD24− cells, although considered much more stem/basal like, 
were not selected for the analysis because these cells constituted a minor population in both 
normal and tumors (Figure 1B and data not shown).
With stemness-associated gene primer sets, normal and tumor cells segregated into two 
distinct groups in patient 1 (Figure 5A). This analysis distinguished tumor cells from normal 
cells much more clearly than the analysis that involved unselected epithelial cells shown in 
Figure 3A. Ingenuity pathway analyses of genes that are expressed at higher levels in tumor 
cells compared to normal cells identified two signaling networks; one involving VEGFA, 
WNT5A, SMAD3, and MMP2 and the other involving DNMT3A (Figure 5B). In patient 2, 
tumor cells formed two unique clusters; one being very similar to normal cells and other 
showing very little expression of stemness-associated genes (Figure 5C). Pathways that 
involved β-Catenin signaling and stemness-associated genes SOX9 and SOX17 were 
dominant in the major tumor clone (Figure 5D). In patient 3, tumor cells formed one major 
cluster, which differed from normal cells through differential expression of NGFR and 
SERPINA1 (Figure 5E). Tumor cells also lacked the expression of CDH2, which further 
indicates luminal nature of tumor cells. Similar analysis of tumor and normal of patient 4 is 
shown in Figure S1. Tumor cells were enriched for the expression of Wnt/β-Catenin 
pathway genes.
PAM50 gene set analyses provided additional insights. Keratin 14 and keratin 5 expression 
pattern in these phenotypically defined cells was similar to previously reported expression 
pattern in freshly prepared un-cultured CD49f+/EpCAM+ cells (16) suggesting limited 
introduction of culturing artifacts in gene expression analyses. In patient 1, while normal 
cells grouped into one cluster demonstrating basal/luminal hybrid gene expression pattern, 
tumor cells subgrouped into three clusters (Figure 6A). One major cluster is most likely 
luminal B subtype as it expressed mostly luminal genes. Two other minor clusters were 
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enriched for basal or basal/luminal hybrid gene expression pattern. Tumor samples of patient 
2 also formed two distinct clusters; one expressing mostly luminal genes, while the other 
expressing both luminal and basal genes (Figure 6B). Tumor cells in patient 3 are mostly 
homogenous expressing predominantly luminal genes and few basal genes (Figure 6C). 
However, normal cells in this case clustered into two clusters; one leaning towards luminal 
and the other being luminal/basal hybrid. Note that basal/luminal hybrid gene expression 
pattern is not unique to cultured cells and is observed in primary tumor samples (33).
Clustering analysis of combined unselected and phenotypically defined cell population
It is often difficult to distinguish tumor cells from normal cells that may be embedded in the 
tumor and such cross contamination could impact data interpretation in single cell RNA 
analysis. To address this issue, we performed unsupervised clustering of all cells from a 
patient sample. In the PAM50 analyses of cells from patient 1, the majority of tumor cells 
separated into two large clusters with very few tumor cells interspersed within two clusters 
of normal cells (Figure S2). In stemness gene set analysis, normal cells formed two distinct 
clusters with very few interspersed tumor cells, whereas tumor cells formed one large cluster 
(Figure S3). Results are similar with cells from patient 2. With PAM50 gene set, normal 
cells formed one cluster expressing both basal and luminal genes, whereas tumor cells 
formed one major cluster and one minor clusters with both clusters expressing mostly 
luminal genes compared to normal cells (Figure S4). With stemness gene set, normal cells 
formed one large cluster expressing both luminal and basal genes, whereas tumor cells 
formed two distinct clusters (Figure S5). As with patient 1, there were very few normal cells 
clustered within the tumor cell cluster suggesting minimum normal cell contamination 
within the tumor. Overall, results presented clearly show the ability of the assay presented in 
this study to document heterogeneity within primary tumor at single cell level. In addition, 
this clustering analysis further documents heterogeneity in gene expression in both normal 
and tumor cells.
Gene expression differences between tumor and normal: cell-type-origin of tumor versus 
transformation-induced
It has often been difficult to determine whether the observed gene expression pattern in a 
tumor is reflection of cancer-specific gene aberration or cell-type-origin of tumor. Towards 
this end, we organized results of qRT-PCR into violin plots, which show dynamic range of 
expression in cells and depict heterogeneity in expression. With phenotypically defined 
population of cells, tumor-specific overexpression of MMP2, CCND1, BAG1 and CTNNA1 
was clearly evident in patient 1 (Figure 7A). Analyses of data from unselected cells 
demonstrated a wide range of heterogeneity in expression patterns in both tumor and 
adjacent normal cells and the number of genes that could be considered differentially 
expressed between tumor and normal cells dropped significantly (Figure 7B). For example, 
although overall expression of NGFR appeared to be lower in tumor cells compared to 
adjacent normal cells, tumor contained two populations of cells, one with NGFR levels 
similar to adjacent normal cells and the other population expressing lower levels of NGFR. 
CDH2 expression appears to be elevated in only a fraction of tumor cells as evident from 
both phenotypically defined and unselected cell analyses. Data from patient 2 (Figure 7C 
and D) also revealed the ability of single cell analyses to identify genes that are truly 
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differentially expressed in tumors. MMP2 was only gene that showed overexpression in both 
tumors compared to normal irrespective of cell types used for comparison. We confirmed 
overexpression of MMP2 in tumors by immunohistochemistry of tumor and adjacent normal 
tissues (Figure S6). Overall, the single cell gene expression studies presented in this study 
enabled identification of major and minor subclones of tumor cells as well as genes truly 
differentially expressed in tumor compared to normal cells.
Discussion
In this study, we used single cell gene expression analyses to further refine methods that can 
be used to decipher tumor heterogeneity at individual patient level, to identify minor tumor 
clones as well as to distinguish genes truly differentially expressed in tumor from genes 
whose expression pattern in tumor suggests cellular precursor of tumor. Although several 
previously used techniques of culturing normal and tumor cells from the breast are often 
biased towards outgrowth of cells with basal cell characteristics, single cell analyses clearly 
showed that the method used in our study enabled growth of both normal and tumor cells 
with luminal gene expression pattern. Therefore, we believe that any artifacts introduced due 
to culturing are minimum and is the same for both normal and tumor cells. Also note that 
there is no contamination of other cell types because all cells selected for the analyses 
expressed keratins, ERBB2 and EGFR at variable levels. As multiple studies including the 
recently published results of Human Functional Genome Project clearly show enormous 
functional variation in human genome that impacts host-environment interaction at 
individual levels (8,9,25,34), it is critical to develop assays that compare tumor with normal 
from the same patient. Data presented here demonstrate feasibility of comparing tumor and 
normal at individual level.
Ideally, the studies reported here need to be conducted with cells from fresh tissues with 
limited in vitro manipulation. Our attempts to conduct such analyses were unsuccessful due 
to limited number of epithelial cells from fresh tissues. Such studies are feasible only when 
large tumors are available and larger tumors often tend to have significant number of 
necrotic areas. Adjacent normal tissue also tends to have higher levels of fibroblasts and 
adipocytes and yield very few epithelial cells. Therefore, our analyses required enrichment 
of epithelial cells through short-term cultures. Since data were obtained from cultured cells, 
the effect of tumor microenvironment on tumor cell gene expression was not taken into 
consideration. Nonetheless, cell-intrinsic gene expression differences alone were sufficient 
to distinguish tumor from adjacent normal.
Precision therapeutics programs at multiple institutions rely mostly on testing gene 
aberrations at DNA levels to identify cancer-specific signaling networks (35). These assays 
are reliable in characterizing tumors compared to assays that utilize mRNA-based tumor 
characterization although recent studies have revealed limitations even with mutation-based 
assays because selected tumor tissue for DNA analysis may not be representative of entire 
tumor (36). mRNA-based cancer classification suffers from several limitations including 
lack of appropriate normal controls, inter-individual heterogeneity in normal cell gene 
expression, differences in differentiation state between normal and tumors affecting gene 
expression, and the effect of stroma on gene expression in tumor cells. Greater than 2000 
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genes are differentially expressed between luminal/progenitor and mature cells of the breast 
and we have previously demonstrated inter-individual variability in differentiation state of 
normal breast epithelial cells (14,19). Comparative analyses of phenotypically defined cells 
versus unselected cells described in this study clearly showed the need to refine cancer-
specific pathway discovery by excluding confounding factors such as differences in 
differentiation state between normal and tumor cells and to use normal tissue from the same 
individual for comparison. Stemness-related signaling networks that appear to be active in 
tumor cells differed based on types of cells used for comparison. Lack of consideration to 
these aspects may be responsible for limited reproducibility of mRNA-based gene 
expression signatures and even randomly selected gene sets demonstrating prognostic values 
in breast cancer (37).
It has been technically challenging to differentiate genes that are truly differentially 
expressed in tumor compared to normal from genes whose expression pattern in tumor 
suggests cellular precursors of tumor. This knowledge is critical if the focus is to develop 
therapies based on differentially expressed genes. Data presented in Figure 7 clearly indicate 
the power of the analyses presented to identify truly differentially expressed genes in 
tumors. Number of genes differentially expressed in tumor compared to normal is much 
higher in patient 1 compared to patient 2. Further studies with additional samples are needed 
to link results of this type of studies with clinical parameters.
We were able to detect minor clones of tumor cells using the assay system. Although 
bioinformatics approaches have allowed dissection of genome and RNA sequencing data to 
build tumor evolutionary maps and detect minor tumor clones, functional evaluation of these 
minor clones for tumor recurrence or therapy resistance has not been possible. With 
cryopreserved tumor and normal cells from the same patients, the assay presented here 
provides an opportunity to test various drugs for their tumor cell-specific affects and residual 
cells after treatment can then be subjected to single cell genomic studies to identify cancer 
cell types that are de novo resistant to treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Single cell analyses scheme and samples analyzed. A) Schematic view of experimental 
design. B) Tumor and adjacent normal cells are in different differentiation state. Flow 
cytometry with CD49f and EpCAM stained cells shows different levels of CD49f+/EpCAM
+ luminal progenitor and CD49f-/EpCAM+ differentiated cells in tumor and adjacent 
normal cells of three samples analyzed. Unstained or weakly CD49f stained cells correspond 
to feeder fibroblasts.
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Figure 2. 
Flow cytometry sorting of cells for single cell analyses. A) Jam-A/EpCAM staining to 
separate breast epithelial cells from feeder layer fibroblasts. Fibroblasts do not stain for Jam-
A/EpCAM. Jam-A/EpCAM positive cells were sorted and used for unselected cell analyses. 
B) Sorting of ALDH+/CD49f+/EpCAM+ cells to enrich for phenotypically defined cell 
population. CD49f+/EpCAM+ cells in the boxed regions on right were selected for analyses.
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Figure 3. 
Genes linked to stemness differentiate tumor cells from normal cells. A) Heatmap depicting 
expression pattern of stemness-associated genes in unselected cells of tumor and adjacent 
normal of patient 1. A vertical bar on right side denotes genes overexpressed in tumor cells 
compared to normal cells. Red and green bars at the bottom indicate normal and tumor cells, 
respectively. B) Heatmap depicting expression pattern of stemness-associated genes in 
unselected cells of tumor and adjacent normal of patient 2. A vertical bar on the right side 
denotes genes that are expressed at a lower level in tumor cells compared to normal. C) 
Stemness cell signaling network uniquely active in tumor cells of patient 1. Network was 
generated using genes indicated by a vertical bar in A. Genes with shaded boxes in the 
network are differentially expressed in tumor cells compared to normal cells. D) Signaling 
network in tumor cells in patient 2. Negative regulators of Wnt signaling pathway such as 
AXIN1 and APC were expressed at lower levels in tumor cells compared to normal cells.
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Figure 4. 
PAM50 gene set analyses identify cells with luminal-enriched, basal-enriched or hybrid gene 
expression patterns. A) Heatmap depicting expression pattern of PAM50 genes in unselected 
cells of tumor and adjacent normal of patient 1. Red and green bars at the bottom indicate 
normal and tumor cells, respectively. Unlike with stemness-associated gene set analyses, 
tumor and normal did not separate clearly into two groups. B) Heatmap depicting expression 
pattern of PAM50 genes in tumor and normal cells of patient 2.
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Figure 5. 
Distinct clustering of ALDH+/CD49f+/EpCAM+ undifferentiated normal and tumor luminal 
progenitor cells. A) Heatmap depicting expression pattern of stemness-associated genes in 
phenotypically defined cells of tumor and adjacent normal of patient 1. B) Genes 
differentially expressed in tumor cells compared to normal cells were part of two signaling 
networks. C) Heatmap depicting expression patterns of stemness-associated genes in normal 
and tumor cells of patient 2. Tumors clustered into two distinct groups. D) Signaling 
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network involving β-Catenin-SOX9-SOX17 was active in the major tumor clone. E). 
Heatmap depicting stemness-associated gene expression in patient 3.
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Figure 6. 
PAM50 gene set analyses of phenotypically defined cells identify multiple tumor clones. A) 
Tumor cells in patient 1 clustered into three distinct groups, each expressing different levels 
of luminal and basal genes. B) Expression pattern of PAM50 genes in patient 2. Tumor cells 
formed two clusters. C) Tumor cells in patient 3 are relatively homogenous with tumor cells 
clustering into one group expressing mostly luminal genes.
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Figure 7. 
Identifying genes truly differentially expressed in tumors compared to normal. Violin plots 
show genes truly overexpressed or underexpressed in all tumor cells compared to all normal 
cells. Width of the violin depicts expression frequency at that level. A) Data from 
phenotypically defined cells of patient 1. B) Data from unselected cells of patient 1. C) Data 
from phenotypically defined cells of patient 2. D) Data from unselected cells of patient 2.
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